S18 Longitudinal Assessment of Biomarkers for Clinical Trials of Novel Therapeutic Agents: The Run-In Study

Thorax - United Kingdom
doi 10.1136/thx.2010.150912.18
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017

JAMA network open
Medicine
2020English

Novel Cardiovascular Biomarkers and Implications for Clinical Trials

Nature Clinical Practice Cardiovascular Medicine
2006English

Development of Dietary Phytochemical Chemopreventive Agents: Biomarkers and Choice of Dose for Early Clinical Trials

Cancer Prevention Research
MedicineCancer ResearchOncology
2009English

Pmu72 - Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the Fda, 2015-2016

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Application of Biomarkers in Clinical Trials for Motor Neuron Disease

Biomarkers in Medicine
BiochemistryDrug DiscoveryClinical Biochemistry
2010English

Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?

British Journal of Cancer
Cancer ResearchOncology
2009English

Criteria for Assessment of Cognitive Impairment in Clinical Trials

The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products
2018English

The Therapeutic Effect of Clinical Trials: Understanding Placebo Response Rates in Clinical Trials – A Secondary Analysis

BMC Medical Research Methodology
EpidemiologyHealth Informatics
2005English

Novel Therapeutic Agents for Relapsed Classical Hodgkin Lymphoma

British Journal of Haematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy